Acumen Pharmaceuticals, Inc. (ABOS): Price and Financial Metrics
ABOS Price/Volume Stats
| Current price | $3.13 | 52-week high | $11.31 |
| Prev. close | $3.15 | 52-week low | $1.81 |
| Day low | $3.12 | Volume | 479,000 |
| Day high | $3.26 | Avg. volume | 381,948 |
| 50-day MA | $3.84 | Dividend yield | N/A |
| 200-day MA | $4.25 | Market Cap | 188.05M |
ABOS Stock Price Chart Interactive Chart >
Acumen Pharmaceuticals, Inc. (ABOS) Company Bio
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
Latest ABOS News From Around the Web
Below are the latest news stories about ACUMEN PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ABOS as an investment opportunity.
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2023 Earnings Call TranscriptAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2023 Earnings Call Transcript November 13, 2023 Acumen Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.24, expectations were $-0.31. Presentation: Operator: Good day, ladies and gentlemen. Thank you for standing by. Welcome to Acumen Pharma Third Quarter 2023 Conference Call and Webcast. At this time, all participants are in […] |
Q3 2023 Acumen Pharmaceuticals Inc Earnings CallQ3 2023 Acumen Pharmaceuticals Inc Earnings Call |
Acumen Pharmaceuticals Inc (ABOS) Reports Q3 2023 Financial Results and Provides Business UpdateKey Developments Include Progress on Alzheimer's Treatment and New Funding Agreements |
Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals?InvestorsObserver issues critical PriceWatch Alerts for TIVC, TYGO, TATT, PSTV, and ABOS. |
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVenturesProvides additional capital to support development of a subcutaneous formulation of ACU193 and general corporate purposes$30 million drawn down at loan closing CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (“AβOs”) for the treatment of Alzheimer’s disease (“AD”), today announced that it has e |
ABOS Price Returns
| 1-mo | -27.21% |
| 3-mo | -3.10% |
| 6-mo | -2.80% |
| 1-year | -17.20% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -18.49% |
| 2023 | -28.89% |
| 2022 | -20.12% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...